MCID: CND004
MIFTS: 60

Candidiasis

Categories: Blood diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Candidiasis

MalaCards integrated aliases for Candidiasis:

Name: Candidiasis 12 76 55 3 44 15 73
Systemic Candidiasis 12 53 73
Invasive Candidiasis 53 3 73
Disseminated Candidiasis 12 55
Systemic Candida Infections 53

Classifications:



External Ids:

Disease Ontology 12 DOID:1508
ICD10 33 B37 B37.9
ICD9CM 35 112 112.9
MeSH 44 D002177
NCIt 50 C26711
SNOMED-CT 68 78048006

Summaries for Candidiasis

NIH Rare Diseases : 53 Systemic candidiasis includes a spectrum of yeast infections caused by different species (types) of Candida. It is a serious infection that can affect the blood, heart, brain, eyes, bones, or other parts of the body. Although there are over 200 species of Candida, five different species of Candida cause 90% of systemic candidiasis. The most common form of this invasive yeast infection is when Candida enters the bloodstream (candidemia). Signs of candidemia include fever and chills that do not improve with antibiotics. Symptoms of other types of systemic candidiasis depend on the organ or system which is infected. Systemic candidiasis is the most common fungal infection among hosptilized people in high-income countries, including the United States. Diagnosis can be difficult, especially when the Candida is not found in the bloodstream. Treatment usually includes consists of oral or intravenous (IV) antifungal medications. 

MalaCards based summary : Candidiasis, also known as systemic candidiasis, is related to candidiasis, familial, 2 and oral candidiasis. An important gene associated with Candidiasis is AIRE (Autoimmune Regulator), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Fluconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and heart, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 An opportunistic mycosis that involves fungal infection of the mouth, throat, skin, scalp, vagina, fingers, nails, bronchi, lungs, heart and brain by Candida species, of which Candida albicans is the most common. Systemic Candida infections are usually confined to severely immunocompromised persons.

CDC : 3 Photomicrograph of the fungus Candida albicans

Wikipedia : 76 Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Related Diseases for Candidiasis

Diseases in the Candidiasis family:

Candidiasis, Familial, 1 Candidiasis, Familial, 2
Candidiasis, Familial, 3 Candidiasis, Familial, 4
Candidiasis, Familial, 6 Candidiasis, Familial, 8
Candidiasis, Familial, 9 Familial Candidiasis

Diseases related to Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 336)
# Related Disease Score Top Affiliating Genes
1 candidiasis, familial, 2 34.2 CARD9 CLEC7A
2 oral candidiasis 34.1 DEFB4A HTN3 SKAP2
3 familial candidiasis 33.7 CANDF1 CANDN1 CARD9 IL17F IL17RA
4 chronic mucocutaneous candidiasis 33.1 AIRE CARD9 CLEC7A IFNG IL10 IL17A
5 aspergillosis 30.7 CLEC7A IFNG IL10
6 cryptococcosis 30.3 CARD9 IFNG PLB1
7 candida glabrata 30.3 APCS HTN3 IFNG SKAP2
8 alopecia areata 30.0 AIRE IFNG IL17A
9 viral infectious disease 30.0 IFNG IL10 STAT1
10 sporotrichosis 29.9 IFNG IL10
11 trichosporonosis 29.8 IFNG IL17A
12 myasthenia gravis 29.8 AIRE IFNG IL10
13 psoriasis 29.7 DEFB4A IFNG IL10 IL17A TRAF3IP2
14 autoimmune disease 29.6 AIRE IFNG IL10 IL17A
15 neurosyphilis 29.6 IL10 IL17A
16 hematopoietic stem cell transplantation 29.6 CLEC7A IFNG IL10
17 coccidioidomycosis 29.6 CARD9 CLEC7A IL10 STAT1
18 uveitis 29.5 IFNG IL10 IL17A
19 human immunodeficiency virus type 1 29.2 APCS HSP90AA1 HTN3 IFNG IL10 STAT1
20 vulvovaginal candidiasis 12.7
21 neonatal candidiasis 12.5
22 esophageal candidiasis 12.5
23 candidiasis, familial, 4 12.5
24 cutaneous candidiasis 12.4
25 candidiasis, familial, 6 12.4
26 candidiasis, familial, 8 12.4
27 candidiasis, familial, 1 12.4
28 candidiasis, familial, 9 12.3
29 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 12.1
30 candidiasis, familial, 3 12.1
31 autoimmune polyendocrine syndrome type 1 12.0
32 immunodeficiency 51 11.9
33 candidal paronychia 11.8
34 immunodeficiency 31c 11.8
35 vaginitis 11.3
36 myeloperoxidase deficiency 11.3
37 median rhomboid glossitis 11.3
38 biotinidase deficiency 11.2
39 immunodeficiency 42 11.1
40 immunodeficiency 32b 10.9
41 reticular dysgenesis 10.9
42 autoimmune polyendocrine syndrome, type ii 10.9
43 severe combined immunodeficiency, x-linked 10.9
44 t-cell receptor-alpha/beta deficiency 10.9
45 immunodeficiency 26 with or without neurologic abnormalities 10.9
46 aids dysmorphic syndrome 10.9
47 immunodeficiency with thymoma 10.9
48 bacterial vaginosis 10.4
49 trichomoniasis 10.3
50 human immunodeficiency virus infectious disease 10.3

Comorbidity relations with Candidiasis via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Chronic Kidney Failure
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Intestinal Obstruction
Paralytic Ileus Protein-Energy Malnutrition
Respiratory Failure

Graphical network of the top 20 diseases related to Candidiasis:



Diseases related to Candidiasis

Symptoms & Phenotypes for Candidiasis

MGI Mouse Phenotypes related to Candidiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 AIRE APCS CARD9 CLEC7A IFNG IL10
2 digestive/alimentary MP:0005381 9.86 AIRE CLEC7A IFNG IL10 IL17A IL17F
3 immune system MP:0005387 9.8 AIRE APCS CARD9 CLEC7A HSP90AA1 IFNG
4 respiratory system MP:0005388 9.23 AIRE CLEC7A IFNG IL10 IL17A IL17F

Drugs & Therapeutics for Candidiasis

Drugs for Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 86386-73-4 3365
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
3
Anidulafungin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 166663-25-8 166548
4
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 18323-44-9 29029
5
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23593-75-1 2812
6
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2 90566-53-3 62924
7
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1397-89-3 5280965 14956
8
Micafungin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 235114-32-6 3081921 477468
9
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
10
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
11
Caspofungin Approved Phase 4,Phase 3,Phase 2,Not Applicable 179463-17-3, 162808-62-0 468682 2826718
12
Dequalinium Approved, Investigational Phase 4 6707-58-0
13
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
14
Terconazole Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 67915-31-5 441383
15
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
16
Racepinephrine Approved Phase 4 329-65-7 838
17
Nystatin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1400-61-9 11953884
18
Metronidazole Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 443-48-1 4173
19
Zinc Approved, Investigational Phase 4 7440-66-6
20
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
21
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
22
Nevirapine Approved Phase 4 129618-40-2 4463
23
Methotrexate Approved Phase 4,Phase 3 59-05-2, 1959-05-2 126941
24
Histamine Approved, Investigational Phase 4,Phase 2 51-45-6, 75614-87-8 774
25
Simethicone Approved Phase 4,Phase 3 8050-81-5
26
Aluminum hydroxide Approved, Investigational Phase 4,Phase 1,Phase 2 21645-51-2
27
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 171228-49-2 147912
28
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 84625-61-6 55283
29
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
30
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
31
Zidovudine Approved Phase 4 30516-87-1 35370
32
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
33
Povidone Approved Phase 4 9003-39-8
34
Promethazine Approved, Investigational Phase 4 60-87-7 4927
35
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
36
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
37
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
38
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
39
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
40
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
41
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
42
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Steroid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 352)
# Name Status NCT ID Phase Drugs
1 Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week Unknown status NCT00537888 Phase 4 fluconazole
2 A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in Intensive Care Unit (ICU) Patients Unknown status NCT01734525 Phase 4 Anidulafungin
3 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Unknown status NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
4 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
5 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
6 An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis Completed NCT01769339 Phase 4 Miconazole plus Hydrocortisone
7 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU) Completed NCT00520234 Phase 4 Caspofungin;Normal Saline
8 Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
9 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
10 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
11 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
12 This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00548262 Phase 4 Anidulafungin;Voriconazole
13 CRITIC - Treatment of Candidemia and Invasive Candidiasis Completed NCT00670657 Phase 4 AmBisome
14 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
15 A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush Completed NCT00000951 Phase 4 Fluconazole
16 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
17 Optimal Dosage of Caspofungin in Critically Ill Patients Completed NCT01994096 Phase 4 Caspofungin
18 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
19 Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
20 Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants Completed NCT00001107 Phase 4 Fluconazole;AmBisome
21 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
22 Effectiveness of Hygiene Solutions on Denture Biofilm Completed NCT02407834 Phase 4
23 A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Completed NCT00647907 Phase 4 Voriconazole
24 Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients Completed NCT01495039 Phase 4 Nystatin
25 Micafungin Pharmacokinetics in Obese Patients Completed NCT03102658 Phase 4 Micafungin
26 Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT) Completed NCT02021123 Phase 4 Anidulafungin 100mg single dose iv
27 Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration Completed NCT02651038 Phase 4 Micafungin
28 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
29 Comparison of Lactobacillus Reuteri and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants Completed NCT01531192 Phase 4 Nystatin
30 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy
31 Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
32 Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins Completed NCT00839540 Phase 4 micafungin;Micafungin;Caspofungin
33 A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
34 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
35 Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals Recruiting NCT03723525 Phase 4
36 Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients Recruiting NCT03490396 Phase 4
37 Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants Not yet recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
38 A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia Terminated NCT01982071 Phase 4 Micafungin
39 Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
40 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4 ciclopirox
41 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
42 Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients Withdrawn NCT00304772 Phase 4 Fluconazole;Micafungin
43 RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section Withdrawn NCT02009098 Phase 4 Cefuroxime
44 Fluconazole Versus Micafungin in Neonates With Candidiasis Unknown status NCT02145832 Phase 2, Phase 3 Fluconazole;Micafungin
45 Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
46 Dysbiosis in Localized Provoked Vulvodynia (LPV) Unknown status NCT02393911 Phase 3
47 Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia Unknown status NCT01270490 Phase 3 Interferon-gamma, Recombinant
48 Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight Completed NCT00734539 Phase 3 fluconazole;placebo
49 A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis Completed NCT00128323 Phase 3 Gentian violet 1% solution;Gentian violet 0.00165% solution;Nystatin solution
50 Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis Completed NCT00666185 Phase 3 Micafungin;Fluconazole

Search NIH Clinical Center for Candidiasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: candidiasis

Genetic Tests for Candidiasis

Anatomical Context for Candidiasis

MalaCards organs/tissues related to Candidiasis:

41
Skin, Brain, Heart, Testes, Colon, Bone, Liver

Publications for Candidiasis

Articles related to Candidiasis:

(show top 50) (show all 2877)
# Title Authors Year
1
Genotyping of Candida albicans and Candida dubliniensis by 25S rDNA analysis shows association with virulence attributes in oral candidiasis. ( 30321765 )
2019
2
Prospective evaluation of lymphocyte subtyping for the diagnosis of invasive candidiasis in non-neutropenic critically ill patients. ( 30399447 )
2019
3
Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. ( 29975334 )
2018
4
New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. ( 29364495 )
2018
5
Experience with I^-D-Glucan Assay in the Management of Critically ill Patients with High Risk of Invasive Candidiasis: An Observational Study. ( 29910549 )
2018
6
Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi'an: A Cross-Sectional Study. ( 29977925 )
2018
7
Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. ( 29790255 )
2018
8
Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center. ( 29702297 )
2018
9
Caspofungin resistant disseminated candidiasis in a 7-year-old girl with T cell lymphoma: a case report. ( 29441283 )
2018
10
Th17 cells differentiated with mycelial membranes of Candida albicans prevent oral candidiasis. ( 29462298 )
2018
11
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate theA efficacy and safety of orally administeredA VT-1161 inA the treatment of recurrentA vulvovaginal candidiasis. ( 29534874 )
2018
12
Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis. ( 29380647 )
2018
13
Clinical characteristics of the first cases of invasive candidiasis in China due to pan-echinocandin-resistant<i>Candida tropicalis</i>and<i>Candida glabrata</i>isolates with delineation of their resistance mechanisms. ( 29416360 )
2018
14
Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. ( 29369937 )
2018
15
VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice. ( 29788070 )
2018
16
Cytology Preparations of Formalin Fixative Aid Detection of Giardia in Duodenal Biopsy Samples: A Helpful Tool for Diagnosing Esophageal Candidiasis as Well? ( 29762142 )
2018
17
Pulsatilla decoction inhibits Candida albicans proliferation and adhesion in a mouse model of vulvovaginal candidiasis via the Dectin-1 signaling pathway. ( 29775695 )
2018
18
Two Cases of Chronic Candidiasis in Keratitis-Ichthyosis-Deafness Syndrome. ( 29742560 )
2018
19
Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. ( 29963049 )
2018
20
Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal candidiasis. ( 28986195 )
2018
21
Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study. ( 29977259 )
2018
22
Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: &amp;quot;Neutrophil Anergy&amp;quot;. ( 29203543 )
2018
23
Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1. ( 29702748 )
2018
24
Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey. ( 29959610 )
2018
25
Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis. ( 29846682 )
2018
26
Cutaneous candidiasis caused by Candida albicans in a young non-immunosuppressed patient: an unusual presentation. ( 29882446 )
2018
27
Diagnosing Invasive Candidiasis. ( 29444828 )
2018
28
Saccharomyces cerevisiae-based probiotic as novel anti-fungal and anti-inflammatory agent for therapy of vaginal candidiasis. ( 29380641 )
2018
29
The effect of a vaginal suppository formulation of dill (Anethum graveolens) in comparison to clotrimazole vaginal tablet on the treatment of vulvovaginal candidiasis. ( 29553834 )
2018
30
Usefulness of A9-D-glucan for diagnosis and follow-up of invasive candidiasis in onco-haematological patients. ( 29432826 )
2018
31
Chronic mucocutaneous candidiasis, a case study and literature review. ( 29500032 )
2018
32
Tetraglochin cristatum (Britton) Roth: a medicinal plant from the Argentinean highlands with potential use in vaginal candidiasis. ( 29307753 )
2018
33
Nanolipid Gel of an Antimycotic Drug for Treating Vulvovaginal Candidiasis-Development and Evaluation. ( 29340981 )
2018
34
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. ( 29902998 )
2018
35
Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. ( 29874389 )
2018
36
Systemic hematogenous dissemination of mouse oral candidiasis is induced by oral mucositis. ( 29797142 )
2018
37
Special Issue: <i>Candida</i> and Candidiasis. ( 29933544 )
2018
38
Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation. ( 29934865 )
2018
39
IL-36 and IL-1/IL-17 Drive Immunity to Oral Candidiasis via Parallel Mechanisms. ( 29891557 )
2018
40
Promising alternative therapeutics for oral candidiasis. ( 29852856 )
2018
41
Amphotericin B-Loaded Plga Nanofibers: an Alternative Therapy Scheme for Local Treatment of Vulvovaginal Candidiasis. ( 29940181 )
2018
42
Patient Susceptibility to Candidiasis-A Potential for Adjunctive Immunotherapy. ( 29371502 )
2018
43
Antimicrobial photodynamic therapy as a new approach for the treatment of vulvovaginal candidiasis: preliminary results. ( 29931589 )
2018
44
Proanthocyanidin polymeric tannins from Stryphnodendron adstringens are effective against Candida spp. isolates and for vaginal candidiasis treatment. ( 29325916 )
2018
45
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. ( 29932786 )
2018
46
RISK FACTORS OF VULVOVAGINAL CANDIDIASIS IN DERMATO-VENEREOLOGY OUTPATIENTS CLINIC OF SOETOMO GENERAL HOSPITAL, SURABAYA, INDONESIA. ( 29619437 )
2018
47
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. ( 29685081 )
2018
48
Chair-Side Direct Microscopy Procedure for Diagnosis of Oral Candidiasis in an Adolescent. ( 29854484 )
2018
49
Prevalence and association of oral candidiasis with dysphagia in individuals with acquired brain injury. ( 29182379 )
2018
50
Amplitude-modulated cold atmospheric pressure plasma jet for treatment of oral candidiasis: In vivo study. ( 29949638 )
2018

Variations for Candidiasis

Expression for Candidiasis

Search GEO for disease gene expression data for Candidiasis.

Pathways for Candidiasis

Pathways related to Candidiasis according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 CARD9 CLEC7A DEFB4A HSP90AA1 HTN3 IFNG
2
Show member pathways
13.12 HSP90AA1 IFNG IL10 IL17A IL17F IL17RA
3
Show member pathways
12.71 HSP90AA1 IFNG IL10 IL17A STAT1
4
Show member pathways
12.39 IFNG IL10 IL17A IL17F STAT1
5 12.35 CARD9 IFNG IL10 IL17A STAT1
6
Show member pathways
12.34 HSP90AA1 IFNG IL10 IL17A IL17F STAT1
7
Show member pathways
12.08 HSP90AA1 IFNG IL10 IL17A STAT1
8
Show member pathways
12.06 CARD9 CLEC7A IL10 STAT1
9 12.02 CARD9 CLEC7A IFNG IL10 STAT1
10
Show member pathways
11.92 IFNG IL10 IL17A IL17RC STAT1
11
Show member pathways
11.77 IFNG IL10 IL17A IL17F STAT1
12 11.7 IFNG IL10 STAT1
13 11.66 HSP90AA1 IFNG STAT1
14 11.64 IFNG IL10 IL17A
15 11.61 HSP90AA1 IL10 IL17A IL17F STAT1
16 11.59 IFNG IL10 IL17RA
17 11.56 IFNG IL10 IL17A
18
Show member pathways
11.56 DEFB4A HSP90AA1 IFNG IL17A IL17F IL17RA
19
Show member pathways
11.32 IL17A IL17F IL17RA IL17RC TRAF3IP2

GO Terms for Candidiasis

Cellular components related to Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 APCS DEFB4A HSP90AA1 HTN3 IFNG IL10

Biological processes related to Candidiasis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.91 AIRE DEFB4A IFNG IL10 IL17A
2 cytokine-mediated signaling pathway GO:0019221 9.8 HSP90AA1 IL10 IL17A IL17F STAT1
3 humoral immune response GO:0006959 9.67 AIRE IFNG TRAF3IP2
4 defense response to fungus GO:0050832 9.56 HTN3 IL17A IL17RA IL17RC
5 defense response to protozoan GO:0042832 9.55 CLEC7A IL10
6 chaperone-mediated protein complex assembly GO:0051131 9.54 APCS HSP90AA1
7 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.52 IFNG STAT1
8 positive regulation of interleukin-6 secretion GO:2000778 9.5 IL17A IL17F IL17RC
9 granulocyte chemotaxis GO:0071621 9.48 IL17RA IL17RC
10 fibroblast activation GO:0072537 9.46 IL17A IL17RA
11 regulation of interleukin-6 biosynthetic process GO:0045408 9.43 CARD9 IL17F
12 regulation of interleukin-2 biosynthetic process GO:0045076 9.37 CARD9 IL17F
13 positive regulation of interleukin-23 production GO:0032747 9.33 IFNG IL17A IL17RA
14 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.26 IL17A IL17F IL17RA IL17RC
15 interleukin-17-mediated signaling pathway GO:0097400 8.92 IL17A IL17F IL17RA IL17RC

Molecular functions related to Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IFNG IL10 IL17A IL17F
2 interleukin-17 receptor activity GO:0030368 8.62 IL17RA IL17RC

Sources for Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....